Search Results - "SIKOV, William"

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) by Sikov, William M, Berry, Donald A, Perou, Charles M, Singh, Baljit, Cirrincione, Constance T, Tolaney, Sara M, Kuzma, Charles S, Pluard, Timothy J, Somlo, George, Port, Elisa R, Golshan, Mehra, Bellon, Jennifer R, Collyar, Deborah, Hahn, Olwen M, Carey, Lisa A, Hudis, Clifford A, Winer, Eric P

“…One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB…”
Get full text

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial by Loibl, Sibylle, O'Shaughnessy, Joyce, Untch, Michael, Sikov, William M, Rugo, Hope S, McKee, Mark D, Huober, Jens, Golshan, Mehra, von Minckwitz, Gunter, Maag, David, Sullivan, Danielle, Wolmark, Norman, McIntyre, Kristi, Ponce Lorenzo, Jose J, Metzger Filho, Otto, Rastogi, Priya, Symmans, W Fraser, Liu, Xuan, Geyer, Charles E

“…Although several randomised trials in patients with triple-negative breast cancer have shown that the addition of carboplatin, with or without poly(ADP-ribose)…”
Get full text

Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates: Surgical Results From CALGB 40603 (Alliance) by Golshan, Mehra, Cirrincione, Constance T, Sikov, William M, Berry, Donald A, Jasinski, Sara, Weisberg, Tracey F, Somlo, George, Hudis, Clifford, Winer, Eric, Ollila, David W

“…OBJECTIVE:To assess the efficacy of neoadjuvant systemic therapy (NST) at increasing the rate of successful breast-conserving therapy (BCT) in triple negative…”
Get full text

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial by Golshan, Mehra, Loibl, Sibylle, Wong, Stephanie M, Houber, Jens Bodo, O'Shaughnessy, Joyce, Rugo, Hope S, Wolmark, Norman, McKee, Mark D, Maag, David, Sullivan, Danielle M, Metzger-Filho, Otto, Von Minckwitz, Gunter, Geyer, Jr, Charles E, Sikov, William M, Untch, Michael

“…Neoadjuvant systemic therapy (NST) is often administered to enable breast-conserving therapy (BCT) in stages II to III breast cancer. To prospectively evaluate…”
Get more information

Assessing the Role of Platinum Agents in Aggressive Breast Cancers by Sikov, William M.

“…As anticipated by their structure and mechanism of action, platinum analogs exhibit clinically significant antitumor activity in the more aggressive forms of…”
Get full text

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 by Mayer, Ingrid A, Zhao, Fengmin, Arteaga, Carlos L, Symmans, William F, Park, Ben H, Burnette, Brian L, Tevaarwerk, Amye J, Garcia, Sofia F, Smith, Karen L, Makower, Della F, Block, Margaret, Morley, Kimberly A, Jani, Chirag R, Mescher, Craig, Dewani, Shabana J, Tawfik, Bernard, Flaum, Lisa E, Mayer, Erica L, Sikov, William M, Rodler, Eve T, Wagner, Lynne I, DeMichele, Angela M, Sparano, Joseph A, Wolff, Antonio C, Miller, Kathy D

“…Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for…”
Get full text

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study by Schumacher, Andrew, Sikov, William M, Quesenberry, Matthew I, Safran, Howard, Khurshid, Humera, Mitchell, Kristen M, Olszewski, Adam J

“…Informed consent forms (ICFs) for oncology clinical trials have grown increasingly longer and more complex. We evaluated objective understanding of critical…”
Get full text

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer by Shepherd, Jonathan H, Ballman, Karla, Polley, Mei-Yin C, Campbell, Jordan D, Fan, Cheng, Selitsky, Sara, Fernandez-Martinez, Aranzazu, Parker, Joel S, Hoadley, Katherine A, Hu, Zhiyuan, Li, Yan, Soloway, Matthew G, Spears, Patricia A, Singh, Baljit, Tolaney, Sara M, Somlo, George, Port, Elisa R, Ma, Cynthia, Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Bellon, Jennifer R, Collyar, Deborah, Hahn, Olwen M, Hudis, Clifford A, Winer, Eric P, Partridge, Ann, Hyslop, Terry, Carey, Lisa A, Perou, Charles M, Sikov, William M

“…CALGB 40603 (NCT00861705), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by…”
Get full text

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer by Braman, Nathaniel, Prasanna, Prateek, Whitney, Jon, Singh, Salendra, Beig, Niha, Etesami, Maryam, Bates, David D B, Gallagher, Katherine, Bloch, B Nicolas, Vulchi, Manasa, Turk, Paulette, Bera, Kaustav, Abraham, Jame, Sikov, William M, Somlo, George, Harris, Lyndsay N, Gilmore, Hannah, Plecha, Donna, Varadan, Vinay, Madabhushi, Anant

“…There has been significant recent interest in understanding the utility of quantitative imaging to delineate breast cancer intrinsic biological factors and…”
Get full text

Bortezomib in combination with infusional dose‐adjusted EPOCH for the treatment of plasmablastic lymphoma by Castillo, Jorge J., Reagan, John L., Sikov, William M., Winer, Eric S.

“…Summary Plasmablastic lymphoma (PBL) is a rare and aggressive CD20‐negative lymphoma. Despite improvements of the biology behind PBL, it still represents a…”
Get full text

Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance) by Weiss, Anna, Campbell, Jordan, Ballman, Karla V., Sikov, William M., Carey, Lisa A., Hwang, E. Shelley, Poppe, Matthew M., Partridge, Ann H., Ollila, David W., Golshan, Mehra

“…Background De-escalation of axillary surgery after neoadjuvant chemotherapy (NAC) requires careful patient selection. We seek to determine predictors of nodal…”
Get full text

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) by Golshan, Mehra, Cirrincione, Constance T., Sikov, William M., Carey, Lisa A., Berry, Donald A., Overmoyer, Beth, Henry, Nora L., Somlo, George, Port, Elisa, Burstein, Harold J., Hudis, Clifford, Winer, Eric, Ollila, David W.

“…Objective It had been previously shown that patients who receive neoadjuvant systemic therapy (NST) are more likely to undergo breast-conserving therapy (BCT)…”
Get full text

Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer by Varadan, Vinay, Gilmore, Hannah, Miskimen, Kristy L S, Tuck, David, Parsai, Shikha, Awadallah, Amad, Krop, Ian E, Winer, Eric P, Bossuyt, Veerle, Somlo, George, Abu-Khalaf, Maysa M, Fenton, Mary Anne, Sikov, William, Harris, Lyndsay N

“…Recent data suggest that intrinsic subtype and immune cell infiltration may predict response to trastuzumab-based therapy. We studied the interaction between…”
Get full text

A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I by Pachman, Deirdre R., Dockter, Travis, Zekan, Patricia J., Fruth, Briant, Ruddy, Kathryn J., Ta, Lauren E., Lafky, Jacqueline M., Dentchev, Todor, Le-Lindqwister, Nguyet Anh, Sikov, William M., Staff, Nathan, Beutler, Andreas S., Loprinzi, Charles L.

“…Purpose Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Given that extensive…”
Get full text

Which patients with early-stage triple-negative breast cancer should receive a platinum? by Sikov, William M

Get full text

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials by Basch, Ethan, Dueck, Amylou C, Rogak, Lauren J, Minasian, Lori M, Kelly, William Kevin, O'Mara, Ann M, Denicoff, Andrea M, Seisler, Drew, Atherton, Pamela J, Paskett, Electra, Carey, Lisa, Dickler, Maura, Heist, Rebecca S, Himelstein, Andrew, Rugo, Hope S, Sikov, William M, Socinski, Mark A, Venook, Alan P, Weckstein, Douglas J, Lake, Diana E, Biggs, David D, Freedman, Rachel A, Kuzma, Charles, Kirshner, Jeffrey J, Schrag, Deborah

“…In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reported by investigators rather than by patients. There is increasing…”
Get more information

Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) by Warner, Erica T., Ballman, Karla V., Strand, Carrie, Boughey, Judy C., Buzdar, Aman U., Carey, Lisa A., Sikov, William M., Partridge, Ann H.

“…Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese,…”
Get full text

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131 by Smith, Karen L., Zhao, Fengmin, Mayer, Ingrid A., Tevaarwerk, Amye J., Garcia, Sofia F., Arteaga, Carlos L., Symmans, William F., Park, Ben H., Burnette, Brian L., Makower, Della F., Block, Margaret, Morley, Kimberly A., Jani, Chirag R., Mescher, Craig, Dewani, Shabana J., Brown‐Glaberman, Ursa, Flaum, Lisa E., Mayer, Erica L., Sikov, William M., Rodler, Eve T., DeMichele, Angela M., Sparano, Joseph A., Wolff, Antonio C., Miller, Kathy D., Wagner, Lynne I.

“…Background Patient‐reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment‐associated adverse…”
Get full text

Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer by Brodsky, Alexander S, Xiong, Jinjun, Yang, Dongfang, Schorl, Christoph, Fenton, Mary Anne, Graves, Theresa A, Sikov, William M, Resnick, Murray B, Wang, Yihong

“…The influence of the tumor microenvironment and tumor-stromal interactions on the heterogeneity of response within breast cancer subtypes have just begun to be…”
Get full text

Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy by Regen-Tuero, Helaina C, Ward, Robert C, Sikov, William M, Littrup, Peter J

“…Cryoablation is a well-tolerated outpatient procedure that has been used to treat metastatic sites as well as small breast cancers in patients who are…”
Get full text